JP2002541102A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002541102A5 JP2002541102A5 JP2000609059A JP2000609059A JP2002541102A5 JP 2002541102 A5 JP2002541102 A5 JP 2002541102A5 JP 2000609059 A JP2000609059 A JP 2000609059A JP 2000609059 A JP2000609059 A JP 2000609059A JP 2002541102 A5 JP2002541102 A5 JP 2002541102A5
- Authority
- JP
- Japan
- Prior art keywords
- chloro
- hydrogen
- fluoro
- compound
- bromo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052739 hydrogen Inorganic materials 0.000 description 22
- 239000001257 hydrogen Substances 0.000 description 22
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 13
- IQHSSYROJYPFDV-UHFFFAOYSA-N 2-bromo-1,3-dichloro-5-(trifluoromethyl)benzene Chemical group FC(F)(F)C1=CC(Cl)=C(Br)C(Cl)=C1 IQHSSYROJYPFDV-UHFFFAOYSA-N 0.000 description 11
- 125000001309 chloro group Chemical group Cl* 0.000 description 6
- 150000002431 hydrogen Chemical class 0.000 description 6
- -1 chloro-4-fluorostyryl-4-bromobenzylsulfone Chemical compound 0.000 description 5
- 125000001153 fluoro group Chemical group F* 0.000 description 5
- 125000001246 bromo group Chemical group Br* 0.000 description 4
- 125000004093 cyano group Chemical group *C#N 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- SKUSOFLZORLIEM-WXUKJITCSA-N 2,6-dichloro-5-[[4,6-dichloro-6-[(E)-2-(4-fluorophenyl)ethenyl]cyclohexa-2,4-dien-1-yl]methylsulfonylmethyl]-6-[(E)-2-(4-fluorophenyl)ethenyl]cyclohexa-1,3-diene Chemical compound ClC1(C(CS(=O)(=O)CC2C(C=C(C=C2)Cl)(Cl)\C=C\C2=CC=C(C=C2)F)C=CC(=C1)Cl)\C=C\C1=CC=C(C=C1)F SKUSOFLZORLIEM-WXUKJITCSA-N 0.000 description 2
- OURXDSGAVKVASU-WXUKJITCSA-N 6-chloro-5-[[6-chloro-4-fluoro-6-[(E)-2-(4-fluorophenyl)ethenyl]cyclohexa-2,4-dien-1-yl]methylsulfonylmethyl]-2-fluoro-6-[(E)-2-(4-fluorophenyl)ethenyl]cyclohexa-1,3-diene Chemical compound ClC1(C(CS(=O)(=O)CC2C(C=C(C=C2)F)(Cl)\C=C\C2=CC=C(C=C2)F)C=CC(=C1)F)\C=C\C1=CC=C(C=C1)F OURXDSGAVKVASU-WXUKJITCSA-N 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- ZFCJOKDGBOQUHE-IAGONARPSA-N 1,2-dichloro-4-[(e)-1-[(e)-1-(3,4-dichlorophenyl)-3-(4-fluorophenyl)prop-2-enyl]sulfonyl-3-(4-fluorophenyl)prop-2-enyl]benzene Chemical compound C1=CC(F)=CC=C1\C=C\C(S(=O)(=O)C(\C=C\C=1C=CC(F)=CC=1)C=1C=C(Cl)C(Cl)=CC=1)C1=CC=C(Cl)C(Cl)=C1 ZFCJOKDGBOQUHE-IAGONARPSA-N 0.000 description 1
- QWFMTLKXRKICBE-HMMKTVFPSA-N 1-[(e)-3-(2,4-dichlorophenyl)-3-[(e)-1-(2,4-dichlorophenyl)-3-[4-fluoro-2-(trifluoromethyl)phenyl]prop-2-enyl]sulfonylprop-1-enyl]-4-fluoro-2-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC(F)=CC=C1\C=C\C(S(=O)(=O)C(\C=C\C=1C(=CC(F)=CC=1)C(F)(F)F)C=1C(=CC(Cl)=CC=1)Cl)C1=CC=C(Cl)C=C1Cl QWFMTLKXRKICBE-HMMKTVFPSA-N 0.000 description 1
- BBGVNVQJAOKNDB-BGPOSVGRSA-N 1-[(e)-3-(4-bromophenyl)-3-[(e)-1-(4-bromophenyl)-3-(2,4-dichlorophenyl)prop-2-enyl]sulfonylprop-1-enyl]-2,4-dichlorobenzene Chemical compound ClC1=CC(Cl)=CC=C1\C=C\C(S(=O)(=O)C(\C=C\C=1C(=CC(Cl)=CC=1)Cl)C=1C=CC(Br)=CC=1)C1=CC=C(Br)C=C1 BBGVNVQJAOKNDB-BGPOSVGRSA-N 0.000 description 1
- IAYIWJYDIFPAOY-BGPOSVGRSA-N 1-[(e)-3-(4-bromophenyl)-3-[(e)-1-(4-bromophenyl)-3-(2,4-difluorophenyl)prop-2-enyl]sulfonylprop-1-enyl]-2,4-difluorobenzene Chemical compound FC1=CC(F)=CC=C1\C=C\C(S(=O)(=O)C(\C=C\C=1C(=CC(F)=CC=1)F)C=1C=CC(Br)=CC=1)C1=CC=C(Br)C=C1 IAYIWJYDIFPAOY-BGPOSVGRSA-N 0.000 description 1
- LWGAIVRNIKEXQA-OGBZJDJUSA-N 1-[(e)-3-(4-bromophenyl)-3-[(e)-1-(4-bromophenyl)-3-(4-nitrophenyl)prop-2-enyl]sulfonylprop-1-enyl]-4-nitrobenzene Chemical compound C1=CC([N+](=O)[O-])=CC=C1\C=C\C(S(=O)(=O)C(\C=C\C=1C=CC(=CC=1)[N+]([O-])=O)C=1C=CC(Br)=CC=1)C1=CC=C(Br)C=C1 LWGAIVRNIKEXQA-OGBZJDJUSA-N 0.000 description 1
- VPGMURFDVKBUDH-BGPOSVGRSA-N 1-[(e)-3-(4-chlorophenyl)-3-[(e)-1-(4-chlorophenyl)-3-(2,4-difluorophenyl)prop-2-enyl]sulfonylprop-1-enyl]-2,4-difluorobenzene Chemical compound FC1=CC(F)=CC=C1\C=C\C(S(=O)(=O)C(\C=C\C=1C(=CC(F)=CC=1)F)C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 VPGMURFDVKBUDH-BGPOSVGRSA-N 0.000 description 1
- DBDXKKQHXKYQLG-OGBZJDJUSA-N 1-[(e)-3-(4-fluorophenyl)-3-[(e)-1-(4-fluorophenyl)-3-(4-nitrophenyl)prop-2-enyl]sulfonylprop-1-enyl]-4-nitrobenzene Chemical compound C1=CC([N+](=O)[O-])=CC=C1\C=C\C(S(=O)(=O)C(\C=C\C=1C=CC(=CC=1)[N+]([O-])=O)C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 DBDXKKQHXKYQLG-OGBZJDJUSA-N 0.000 description 1
- ZWSNYXWDSHRSMX-KVJLFNRQSA-N 1-[(e)-3-(4-methoxyphenyl)-3-[(e)-1-(4-methoxyphenyl)-3-(4-nitrophenyl)prop-2-enyl]sulfonylprop-1-enyl]-4-nitrobenzene Chemical compound C1=CC(OC)=CC=C1C(S(=O)(=O)C(\C=C\C=1C=CC(=CC=1)[N+]([O-])=O)C=1C=CC(OC)=CC=1)\C=C\C1=CC=C([N+]([O-])=O)C=C1 ZWSNYXWDSHRSMX-KVJLFNRQSA-N 0.000 description 1
- ZURPRGSVWOXMCZ-KVJLFNRQSA-N 1-bromo-4-[(e)-3-[(e)-3-(4-bromophenyl)-1-(4-methoxyphenyl)prop-2-enyl]sulfonyl-3-(4-methoxyphenyl)prop-1-enyl]benzene Chemical compound C1=CC(OC)=CC=C1C(S(=O)(=O)C(\C=C\C=1C=CC(Br)=CC=1)C=1C=CC(OC)=CC=1)\C=C\C1=CC=C(Br)C=C1 ZURPRGSVWOXMCZ-KVJLFNRQSA-N 0.000 description 1
- QQMWXKDUAGXAFW-OGBZJDJUSA-N 1-fluoro-4-[(e)-3-[(e)-3-(4-fluorophenyl)-1-(4-nitrophenyl)prop-2-enyl]sulfonyl-3-(4-nitrophenyl)prop-1-enyl]benzene Chemical compound C1=CC([N+](=O)[O-])=CC=C1C(S(=O)(=O)C(\C=C\C=1C=CC(F)=CC=1)C=1C=CC(=CC=1)[N+]([O-])=O)\C=C\C1=CC=C(F)C=C1 QQMWXKDUAGXAFW-OGBZJDJUSA-N 0.000 description 1
- PTXRVHYRFPXJKU-OGBZJDJUSA-N 1-fluoro-4-[(e)-3-[(e)-3-(4-fluorophenyl)-1-[4-(trifluoromethyl)phenyl]prop-2-enyl]sulfonyl-3-[4-(trifluoromethyl)phenyl]prop-1-enyl]benzene Chemical compound C1=CC(F)=CC=C1\C=C\C(S(=O)(=O)C(\C=C\C=1C=CC(F)=CC=1)C=1C=CC(=CC=1)C(F)(F)F)C1=CC=C(C(F)(F)F)C=C1 PTXRVHYRFPXJKU-OGBZJDJUSA-N 0.000 description 1
- CMXFGRBYOKHMGL-IAGONARPSA-N 2,4-dichloro-1-[(e)-1-[(e)-1-(2,4-dichlorophenyl)-3-(4-fluorophenyl)prop-2-enyl]sulfonyl-3-(4-fluorophenyl)prop-2-enyl]benzene Chemical compound C1=CC(F)=CC=C1\C=C\C(S(=O)(=O)C(\C=C\C=1C=CC(F)=CC=1)C=1C(=CC(Cl)=CC=1)Cl)C1=CC=C(Cl)C=C1Cl CMXFGRBYOKHMGL-IAGONARPSA-N 0.000 description 1
- BYFPPMHMOLVMGF-BGPOSVGRSA-N 2,4-dichloro-1-[(e)-3-(4-chlorophenyl)-3-[(e)-1-(4-chlorophenyl)-3-(2,4-dichlorophenyl)prop-2-enyl]sulfonylprop-1-enyl]benzene Chemical compound C1=CC(Cl)=CC=C1C(S(=O)(=O)C(\C=C\C=1C(=CC(Cl)=CC=1)Cl)C=1C=CC(Cl)=CC=1)\C=C\C1=CC=C(Cl)C=C1Cl BYFPPMHMOLVMGF-BGPOSVGRSA-N 0.000 description 1
- AINNDIMRMZMRRM-BGPOSVGRSA-N 2,4-dichloro-1-[(e)-3-[(e)-3-(2,4-dichlorophenyl)-1-(4-fluorophenyl)prop-2-enyl]sulfonyl-3-(4-fluorophenyl)prop-1-enyl]benzene Chemical compound C1=CC(F)=CC=C1C(S(=O)(=O)C(\C=C\C=1C(=CC(Cl)=CC=1)Cl)C=1C=CC(F)=CC=1)\C=C\C1=CC=C(Cl)C=C1Cl AINNDIMRMZMRRM-BGPOSVGRSA-N 0.000 description 1
- IGHOQZIXSOUKCP-UHFFFAOYSA-N 2-[(2,4-dichlorophenyl)methylsulfonyl]acetic acid Chemical compound OC(=O)CS(=O)(=O)CC1=CC=C(Cl)C=C1Cl IGHOQZIXSOUKCP-UHFFFAOYSA-N 0.000 description 1
- GKJGKCRDFKGLBB-UHFFFAOYSA-N 2-[(3,4-dichlorophenyl)methylsulfonyl]acetic acid Chemical compound OC(=O)CS(=O)(=O)CC1=CC=C(Cl)C(Cl)=C1 GKJGKCRDFKGLBB-UHFFFAOYSA-N 0.000 description 1
- CFJZTCFQMZZZSR-UHFFFAOYSA-N 2-[[4-(trifluoromethyl)phenyl]methylsulfonyl]acetic acid Chemical compound OC(=O)CS(=O)(=O)CC1=CC=C(C(F)(F)F)C=C1 CFJZTCFQMZZZSR-UHFFFAOYSA-N 0.000 description 1
- JJSIGBCBHRFFIG-WXUKJITCSA-N 2-bromo-5-[[4-bromo-6-[(E)-2-(4-bromophenyl)ethenyl]-6-chlorocyclohexa-2,4-dien-1-yl]methylsulfonylmethyl]-6-[(E)-2-(4-bromophenyl)ethenyl]-6-chlorocyclohexa-1,3-diene Chemical compound ClC1(C(CS(=O)(=O)CC2C(C=C(C=C2)Br)(Cl)\C=C\C2=CC=C(C=C2)Br)C=CC(=C1)Br)\C=C\C1=CC=C(C=C1)Br JJSIGBCBHRFFIG-WXUKJITCSA-N 0.000 description 1
- DNVGHJPISKENNC-WXUKJITCSA-N 2-bromo-5-[[4-bromo-6-chloro-6-[(E)-2-(4-fluorophenyl)ethenyl]cyclohexa-2,4-dien-1-yl]methylsulfonylmethyl]-6-chloro-6-[(E)-2-(4-fluorophenyl)ethenyl]cyclohexa-1,3-diene Chemical compound ClC1(C(CS(=O)(=O)CC2C(C=C(C=C2)Br)(Cl)\C=C\C2=CC=C(C=C2)F)C=CC(=C1)Br)\C=C\C1=CC=C(C=C1)F DNVGHJPISKENNC-WXUKJITCSA-N 0.000 description 1
- XHHUIUHBUNSNOW-LQGKIZFRSA-N 4-[(e)-1-[(e)-1-(4-cyanophenyl)-3-(4-fluorophenyl)prop-2-enyl]sulfonyl-3-(4-fluorophenyl)prop-2-enyl]benzonitrile Chemical compound C1=CC(F)=CC=C1\C=C\C(S(=O)(=O)C(\C=C\C=1C=CC(F)=CC=1)C=1C=CC(=CC=1)C#N)C1=CC=C(C#N)C=C1 XHHUIUHBUNSNOW-LQGKIZFRSA-N 0.000 description 1
- MWESRGADIBARED-LQGKIZFRSA-N 4-[(e)-1-[(e)-1-(4-cyanophenyl)-3-(4-nitrophenyl)prop-2-enyl]sulfonyl-3-(4-nitrophenyl)prop-2-enyl]benzonitrile Chemical compound C1=CC([N+](=O)[O-])=CC=C1\C=C\C(S(=O)(=O)C(\C=C\C=1C=CC(=CC=1)[N+]([O-])=O)C=1C=CC(=CC=1)C#N)C1=CC=C(C#N)C=C1 MWESRGADIBARED-LQGKIZFRSA-N 0.000 description 1
- QQCGTYLJFFACIC-WXUKJITCSA-N 6-[(E)-2-(4-bromophenyl)ethenyl]-5-[[6-[(E)-2-(4-bromophenyl)ethenyl]-6-chloro-4-fluorocyclohexa-2,4-dien-1-yl]methylsulfonylmethyl]-6-chloro-2-fluorocyclohexa-1,3-diene Chemical compound ClC1(C(CS(=O)(=O)CC2C(C=C(C=C2)F)(Cl)\C=C\C2=CC=C(C=C2)Br)C=CC(=C1)F)\C=C\C1=CC=C(C=C1)Br QQCGTYLJFFACIC-WXUKJITCSA-N 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000000571 Fibrocystic breast disease Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000009905 Neurofibromatoses Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000016738 bone Paget disease Diseases 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 208000011803 breast fibrocystic disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000007118 chronic progressive multiple sclerosis Diseases 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 208000011379 keloid formation Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 201000004931 neurofibromatosis Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12768399P | 1999-04-02 | 1999-04-02 | |
| US14397599P | 1999-07-15 | 1999-07-15 | |
| US60/127,683 | 1999-07-15 | ||
| US60/143,975 | 1999-07-15 | ||
| PCT/US2000/008565 WO2000059495A1 (en) | 1999-04-02 | 2000-03-31 | (e)-styryl sulfone anticancer agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002541102A JP2002541102A (ja) | 2002-12-03 |
| JP2002541102A5 true JP2002541102A5 (enExample) | 2007-05-24 |
| JP4596651B2 JP4596651B2 (ja) | 2010-12-08 |
Family
ID=26825868
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000609059A Expired - Fee Related JP4596651B2 (ja) | 1999-04-02 | 2000-03-31 | （ｅ）−スチリルスルホン抗癌剤 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1173160B1 (enExample) |
| JP (1) | JP4596651B2 (enExample) |
| AT (1) | ATE298234T1 (enExample) |
| AU (1) | AU774738B2 (enExample) |
| CA (1) | CA2366750C (enExample) |
| DE (1) | DE60020954T2 (enExample) |
| WO (1) | WO2000059495A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2388343A1 (en) * | 1999-11-12 | 2001-05-17 | Mark Steven Marshall | Methods for inhibiting neurofibromatosis type 1 (nf1) |
| US6541475B2 (en) * | 2000-04-14 | 2003-04-01 | Temple University - Of The Commonwealth System Of Higher Education | α, β-unsaturated sulfones for treating proliferative disorders |
| US6486210B2 (en) * | 2000-04-14 | 2002-11-26 | Temple University—Of the Commonwealth System of Higher Education | Substituted styryl benzylsulfones for treating proliferative disorders |
| WO2002067913A1 (en) | 2001-02-27 | 2002-09-06 | Temple University-Of The Commonwealth System Of Higher Education | (z)-styrylbenzylsulfones and pharmaceutical uses thereof |
| US6667346B2 (en) | 2001-02-28 | 2003-12-23 | Temple University - Of The Commonwealth System Of Higher Education | Method for protecting cells and tissues from ionizing radiation toxicity with α, β unsaturated aryl sulfones |
| NZ535232A (en) * | 2002-02-28 | 2007-05-31 | Univ Temple | Amino-substituted (E)-2,6-dialkoxystyryl 4-substituted benzylsulfones for treating proliferative disorders |
| AU2004289281C1 (en) * | 2003-11-14 | 2011-12-08 | Onconova Therapeutics, Inc. | Alpha, beta-Unsaturated sulfoxides for treating proliferative disorders |
| AU2005222947B2 (en) * | 2004-03-16 | 2010-12-23 | Onconova Therapeutics Inc. | Substituted phenoxy- and phenylthio- derivatives for treating proliferative disorders |
| US20090306207A1 (en) * | 2005-01-05 | 2009-12-10 | Reddy M V Ramana | Treatment of Drug-Resistant Proliferative Disorders |
| US8664272B2 (en) * | 2006-08-30 | 2014-03-04 | Temple University—Of the Commonwealth System of Higher Education | Composition and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia |
| US8465413B2 (en) | 2010-11-25 | 2013-06-18 | Coloplast A/S | Method of treating Peyronie's disease |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3463774A (en) * | 1963-03-18 | 1969-08-26 | Hoffmann La Roche | Novel 4,1-benzothiazepin-2-(1h)-ones and 4,1-benzothiazepines |
| JPH0641054A (ja) * | 1992-07-27 | 1994-02-15 | Mitsubishi Petrochem Co Ltd | スチリルスルホン誘導体、それを有効成分とする殺菌剤およびその製造方法 |
| TR199801495T2 (xx) * | 1995-06-07 | 1998-09-21 | Eli Lilly And Company | Vinil s�lfoksitler ve sentezlenmeleri i�in bir i�lem. |
| ATE284386T1 (de) * | 1997-10-03 | 2004-12-15 | Univ Temple | Styrolsulfone als antikrebsmittel |
| US6201154B1 (en) * | 1999-03-31 | 2001-03-13 | Temple University-Of The Commonwealth Of Higher Education | Z-styryl sulfone anticancer agents |
| WO2000059494A1 (en) * | 1999-04-02 | 2000-10-12 | Temple University- Of The Commonwealth System Of Higher Education | Styryl sulfone anticancer agents |
| IL149064A0 (en) * | 1999-10-12 | 2002-11-10 | Univ Temple | Method for protecting normal cells from cytotoxicity of chemotherapeutic agents |
-
2000
- 2000-03-31 WO PCT/US2000/008565 patent/WO2000059495A1/en not_active Ceased
- 2000-03-31 AT AT00921553T patent/ATE298234T1/de active
- 2000-03-31 DE DE60020954T patent/DE60020954T2/de not_active Expired - Lifetime
- 2000-03-31 JP JP2000609059A patent/JP4596651B2/ja not_active Expired - Fee Related
- 2000-03-31 AU AU41853/00A patent/AU774738B2/en not_active Ceased
- 2000-03-31 EP EP00921553A patent/EP1173160B1/en not_active Expired - Lifetime
- 2000-03-31 CA CA2366750A patent/CA2366750C/en not_active Expired - Fee Related